Toad venom for Grandma

Biomind Receives Approval for a Third Phase II Clinical Trial for Its 5-MeO-DMT Based BMND08 Candidate for Depression & Anxiety in Alzheimer’s Disease

Could Alzheimer’s patients benefit from one of the most powerful psychedelics? 

Biomind Labs (BMND) will find out in an upcoming study.

The Phase 2 trial, which was just approved by the Argentinian Institutional Review Board, will see if 5-MeO-DMT (a psychedelic found in the venom of the Sonoran Desert toad) can ease depression and anxiety in patients with Alzheimer’s disease.

PDF of article